Intercept Pharmaceuticals focuses on developing and delivering novel medicines for individuals living with rare and serious liver diseases.

Intercept Pharmaceuticals

Intercept Pharmaceuticals | 64,582 followers on LinkedIn. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). 

In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.

Janet Lewis

Chief Information Officer, at Intercept Pharmaceuticals Inc.

William Wallace

Rare Disease Therapeutic Business Specialist at Intercept Pharmaceuticals | 20+ years in the Pharmaceutical Industry | Territory Turnaround…

Grady Mateen

Director, Field Medical, Medical Science Liaison at Intercept Pharmaceuticals

Arash Thranian, PhD., MBA

Over several years, Cecilia was bounced from doctor to doctor until she found someone who finally listened to her concerns and properly diagnosed her with primary biliary cholangitis ( #PBC ). Ensuring patient voices are heard and understood is a critical aspect of healthcare, and especially important when diagnosing and managing #rarediseases . Watch Cecilia recount her experience with PBC.

We had a great time at #ACG2024 discussing the latest scientific research with the #liver community.

As we wrap up #LiverAwarenessMonth , we want to thank all those who contribute to raising awareness for #liverdisease - in October and beyond!

We’re excited to be at #ACG2024 ! Come visit us at booth #831 or at our product theater at 6:15 pm today, October 27.

Receiving a diagnosis in a rare disease like primary biliary cholangitis ( #PBC ) can take a long time, but early detection may lead to better disease management. Listen as Cecilia describes her own hunt for answers. #LiverAwarenessMonth

We were proud to support and attend the Liver Coalition of San Diego 's Liver Excellence Gala! Thank you for all that you do for the #liverdisease community. #LiverAwarenessMonth

Cecilia’s experience with primary biliary cholangitis ( #PBC ) taught her the importance of advocating for herself. Listen as she encourages others to ensure their voices are heard. #LiverAwarenessMonth

In honor of #HispanicHeritageMonth , we spoke with our very own Rosa Rodriguez about why celebrating this month is important: "Empowered Hispanic women in biotech are not just shaping the future of science - they are also forging paths for future generations, proving that innovation knows no boundaries and that diversity drives progress."

Another great year supporting the American Liver Foundation 's National Legacy Gala and gathering with those who have made an impact on the #liverdisease community! #LiverAwarenessMonth

Welcome to Intercept, Dr. Veruska Di Sena ! We're excited to have you join our team as Senior Vice President of Medical Affairs.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 3:06 AM	cd6360f2
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 3:06 AM	64b60ecf
crunchbase trigger	general	Nov 27, 2024 12:50 PM	41b48a9f
crunchbase profile	general
li profile	general	Nov 9, 2024 3:06 AM	00b4839f
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 3:06 AM	601ecde2
news basic	general	Nov 9, 2024 3:06 AM	21639daf
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:INTERCEPTPHARMA

Intercept Pharmaceuticals

Last Close

18.96

07/11 21:00

Market Cap

794.69M

Beta: -

Volume Today

3.91M

Avg: -